Sirnaomics
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | 2.0m | 70.0m | 161m |
| % growth | - | - | - | - | - | 3400 % | 130 % |
| EBITDA | (37.7m) | (214m) | (92.6m) | (71.6m) | (136m) | (220m) | - |
| % EBITDA margin | - | - | - | - | (6800 %) | (314 %) | - |
| Profit | (43.8m) | (213m) | (88.3m) | (78.7m) | (124m) | - | - |
| % profit margin | - | - | - | - | (6200 %) | - | - |
| EV / revenue | - | - | - | - | 15.6x | 0.5x | 0.2x |
| EV / EBITDA | - | -3.8x | -6.2x | -5.6x | -0.2x | -0.1x | - |
| R&D budget | 14.9m | 40.7m | 67.6m | 54.4m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Early VC | ||
| N/A | N/A | Early VC | |
$10.0m | Series B | ||
$25.0m | Series C | ||
| N/A | $11.0m | Series C | |
| N/A | $22.0m | Series C | |
$105m | Series D | ||
$105m | Series E | ||
* | N/A | $50.0m | IPO |
* | HKD8.0m | Grant | |
| Total Funding | AUD431m | ||
Related Content
Recent News about Sirnaomics
EditSirnaomics Inc. is a biopharmaceutical company that focuses on the discovery and development of RNA interference (RNAi) therapeutics. RNAi is a biological process where RNA molecules inhibit gene expression, effectively silencing targeted genes. This technology is particularly promising for treating various diseases, including cancers and viral infections.
The company primarily serves clients in the healthcare sector, including hospitals, research institutions, and pharmaceutical companies. Sirnaomics operates in the global biopharmaceutical market, which is characterized by rapid innovation and significant investment in research and development.
Sirnaomics' business model revolves around developing novel RNAi drug candidates and bringing them through clinical trials to market. They also engage in strategic partnerships to enhance their development capabilities. For instance, they have partnered with Precision NanoSystems to develop and manufacture new RNAi drug candidates using advanced technology platforms.
The company generates revenue through several channels. Primarily, they earn money by licensing their RNAi technologies and drug candidates to larger pharmaceutical companies. Additionally, they may receive milestone payments and royalties from these partnerships. Sirnaomics also benefits from grants and funding aimed at advancing medical research.
Recently, Sirnaomics announced the spin-off of RNAimmune, a subsidiary focused on developing mRNA therapeutics and vaccines. This move allows them to diversify their portfolio and tap into the growing market for mRNA-based treatments, which gained significant attention during the COVID-19 pandemic.
In summary, Sirnaomics is a key player in the biopharmaceutical industry, leveraging RNAi technology to develop innovative treatments for serious diseases. Their strategic partnerships and diversified approach position them well for future growth.
Keywords: RNAi therapeutics, biopharmaceutical, gene silencing, cancer treatment, viral infections, clinical trials, mRNA therapeutics, drug development, Precision NanoSystems, RNAimmune.
